Mateusz Kaczmarek, Author at TechStock²

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Company Overview and Business Model Nocera is a small-cap company that began in the aquaculture technology niche. It designs and builds land-based recirculating aquaculture systems (RAS) – essentially the tanks, filtration equipment, and engineering needed for sustainable fish farms stockanalysis.com.

3 November 2025

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now

3 November 2025

Biotech · Healthcare · Investment · Market Analysis · NASDAQ:TGTX · Stocks

Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Delivers an Earnings Beat in Q3 2025 Dominion Energy turned in strong third-quarter 2025 results, surpassing analyst expectations on the bottom line. The utility reported net income of $1.0 billion for Q3 (about $1.16 per share), up from $934 million ($1.09)

3 November 2025

Corporate Earnings · Data Centers · Energy Industry · NYSE:D · Offshore Wind · Renewable Energy

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its

3 November 2025

Biotech News · FDA Updates · Financial Analysis · Investment Strategies · NYSE:BHVN · Stock Market

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab,

3 November 2025

Biotech · Cancer Research · Immunotherapy · Medical Innovation · NASDAQ:IOVA · Stock Analysis

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop

3 November 2025

Biotechnology · Cancer Research · Future Trends · Investment Analysis · NASDAQ:PHIO · Stock Market

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

Recent News and Updates (Early November 2025) Earnings Release: On November 3, 2025, ON Semiconductor announced its third-quarter 2025 financial results, which were better than expected. The company reported Q3 revenue of $1.55 billion (down roughly 11% year-over-year) and a profit

3 November 2025

Earnings Reports · Financial News · Investment Analysis · Semiconductor Industry · Stock Market

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch

3 November 2025

Biotechnology · FDA News · Gene Therapy · NASDAQ:QURE · Pharma Industry · Stock Market

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

Leadership Transition at MongoDB MongoDB’s announcement on November 3, 2025 signaled a major leadership shake-up for the $29 billion database company. Dev Ittycheria, who has served as CEO since 2014, will be stepping down after an 11-year tenure leading MongoDB markets.ft.com.

3 November 2025

Business · Cloud Computing · Leadership · NASDAQ:MDB · NYSE:NET · Stock Market · Technology

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have

3 November 2025

Dividends · Investment Strategies · Market Outlook · NYSE:PFE · Pharmaceuticals · Stocks

Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Price: Record High After Earnings Surge Amazon’s stock is riding high after its latest earnings triumph. Shares of AMZN skyrocketed ~10% on Friday, Oct. 31 following the Q3 report, pushing the stock to an all-time high in the

3 November 2025

Amazon · Financial News · Investing · Stock Market · Technology

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

The 1300% Rally and Meme Stock Frenzy Opendoor’s stock has experienced a jaw-dropping rally in 2025, transforming from a penny-stock into a retail trading sensation. After languishing below $1 per share through mid-year (and drawing a Nasdaq delisting warning), OPEN

3 November 2025

Financial News · Investing · Meme Stocks · NASDAQ:OPEN · Real Estate · Stock Market